In the Phase 1b/2 trial, zoci, a potential first-in-class DLL3-targeting antibody drug conjugate, demonstrated clinically meaningful responses in patients with previously treated advanced extrapulmonary neuroendocrine
Zai Lab anticipates major catalysts in 2027 across multiple global programs with transformative potential:
Zoci 1.6 mg/kg plus atezolizumab showed compelling 1L SCLC data at ESMO: 81.8% confirmed ORR, an estimated
At the recommended Phase 3 dose (RP3D) of 1.6 mg/kg, zoci plus atezolizumab achieved a confirmed objective response rate of 81.8% (27/33) and an estimated 6-month progression-free survival rate of 81.9% (n=33) in 1L
Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) an innovation-driven, global biopharma company, today announced that it has entered into a securities purchase agreement for the sale of 11,340,000 American Depositary Shares
- Company to host conference call and webcast on November 5, 2026, at 8:00 a.m. ET (9:00 p.m. HKT)
Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) today announced that it will report its third quarter 2026 financial
- Findings from healthy volunteers in the Phase 1/1b trial will be shared at ACAAI 2026 Annual Scientific Meeting
- Previous non-clinical studies demonstrated the potential for ZL-1503 to provide rapid itch relief and
Poster presentation at ESMO Congress 2026 will highlight findings from trial of zoci in combination with atezolizumab with and without carboplatin
Data adds to body of evidence supporting zoci as a potential
Study met primary endpoint of mean Total Improvement Score (TIS) at Week 52 in the combined study population of IMNM and DM patients (p=0.0011)
Patient improvements observed early and sustained throughout study;
The Company advanced multiple global oncology and immunology programs toward key clinical and regulatory milestones, with significant pipeline catalysts expected in the second half of 2026
Global Phase 1 data for
- NECs are aggressive malignancies with poor prognoses and limited treatment options, representing significant unmet patient need
- U.S. FDA Orphan Drug Designation (ODD) follows receipt of ODD for zoci in pulmonary
- Company to host conference call and webcast on August 6, 2026, at 8:00 a.m. ET (8:00 p.m. HKT)
Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) today announced that it will report its second quarter 2026 financial
- European Medicines Agency's Committee for Orphan Medicinal Products recognized zoci's preliminary clinical data as suggestive of a clinically relevant advantage over currently authorized therapies in relapsed or
- TIVDAK is the first antibody-drug conjugate (ADC) approved for the treatment of previously treated recurrent or metastatic cervical cancer in China
- TIVDAK demonstrated a statistically significant overall survival
Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) today announced changes to its senior leadership team aimed at strengthening operational performance and efficiency. As part of these changes, the Board has made the decision
- epNECs are aggressive malignancies with poor prognosis and no approved therapies, representing significant unmet medical need
- Preliminary clinical data recently presented at the AACR Annual Meeting suggest zoci has
